Exploring graphene oxide nanocomposites in cancer therapy

Title : Exploring graphene oxide nanocomposites in cancer therapy

Abstract:

In this keynote talk, the use of the Hill model to assess the Benchmark dose (BMD), the lethal dose 50 (LD50), the cooperativity (E) and the dissociation constant (K) while analyzing cell viability data using nanomaterials will be explored. The presentation is addressed to discuss the antitumor potential while combining radiofrequency (RF) therapy and selected nanomaterials. In particular, it will be discussed the use of nanocomposites, for instance those comprising graphene oxide (GO) surface functionalized with polyethyleneimine (PEI) and decorated with gold nanoparticles (GO-PEI-Au). Data collected from the cell viability assays using different tumor cell lines (e.g. LLC-WRC-256 and B16-F10) will be presented and discussed. The findings will demonstrate that while the tested nanocomposite (e.g. GO-PEI-Au) may be biocompatible against different cancer cell lines in the absence of radiofrequency (nRF), the application of radiofrequency (RF) enhances the cell toxicity by orders of magnitude, pointing to prospective studies with the tested cell lines using tumor animal models.

Biography:

Professor De Morais (H59), PhD, full Professor of Physics at the University of Brasilia (UnB) – Brazil up to 2013. Appointed as UnB’s (Brazil) Emeritus Professor (2014); Visiting Professor at the Huazhong University of Science and Technology (HUST) – China (2012-2015); Distinguished Professor at the Anhui University (AHU) – China (2016-2019); Full Professor at the Catholic University of Brasília – Brazil since 2018; 2007 Master Research Prize from UnB. He held two-years (1987-1988) position with Bell Communications Research, New Jersey – USA. Doctoral degree in Solid State Physics (1986) from the Federal University of Minas Gerais – Brazil. With more than 13,500 citations, He has published more than 500 papers (Web of Science), presented more than 200 international invited talks, and filed 16 patents.